Loading…
← CockpitCompetitor Analysis › 688806.SS Zhuhai Trinomab Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Zhuhai Trinomab Pharmaceutical Co., Ltd. Class A688806.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Chinese biopharma developing monoclonal antibody drugs, including anti-infective antibody candidates; specifics not fully established.

Mkt cap
$1.32B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$16.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-110.8 pp
WACC 6.3%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥19.54
1D-5.0%
1W-15.5%
1M-16.2%
3M-29.9%
6Mn/a
YTDn/a
1Yn/a
ATR %8.1%
52w lowhigh62.8% off high

What Zhuhai Trinomab Pharmaceutical does

Chinese biopharma developing monoclonal antibody drugs, including anti-infective antibody candidates; specifics not fully established.

Where it sits in the supply chain

  • Health Care
  • Biopharmaceuticals
  • Monoclonal antibodies

Moat: none

Headquarters: Zhuhai, China · Employees: 843

Zhuhai Trinomab Pharmaceutical at a glance

Size Zhuhai Trinomab Pharmaceutical (688806.SS) is a China Health Care company (Biotechnology) with a market value of $1.32B, the 1710th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥19.54 on 18 Nov 2026.

Growth Revenue grew 237.6% over the last twelve months (peer median +13.0%); the operating margin is -1,195.9% (peer median -38.9%).

Valuation It trades at 164.8× enterprise value to sales against a peer median of 8.4× (5th most expensive of 19).

Capital Return on invested capital runs 110.8 points below its cost of capital (6.3% WACC).

Zhuhai Trinomab Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023
Revenuen/aCN¥50.8MCN¥15.1MCN¥0
Revenue growth—+238%——
Gross profitn/a-CN¥11.9M-CN¥55.1M-CN¥62.3M
EBITDAn/a-CN¥554M-CN¥460M-CN¥406M
Net incomen/a-CN¥601M-CN¥515M-CN¥446M
Free cash flown/a-CN¥599M-CN¥378M-CN¥321M
Capital expendituren/aCN¥22.4MCN¥16.3MCN¥20.9M
Total debtCN¥875MCN¥696MCN¥402MCN¥204M

Quarterly statements and history in the cockpit →

Zhuhai Trinomab Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×250×500×750×NVAXNUVBGENBTSHA4588ABSIQURE688765688806.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhuhai Trinomab Pharmaceutical is the large dot.

Zhuhai Trinomab Pharmaceutical competitors and peer comparison

How Zhuhai Trinomab Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhuhai Trinomab Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure688806.SSPeer medianRank in peer set
1-month return-16.2%-15.2%10th lowest of 21
Distance from 52-week high-62.8%-46.5%3rd lowest of 21
Revenue growth (TTM)+237.6%+13.0%3rd highest of 18
Operating margin-1,195.9%-38.9%3rd lowest of 19
EV / Sales164.8×8.4×5th most expensive of 19
ROIC minus cost of capital-110.8 pp-6.9 pplowest of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Zhuhai Trinomab Pharmaceutical 688806.SSChina$1.32Bn/a+238%-1,196%164.8×n/an/a
Novavax NVAXUnited States$1.31B-14%-61%-17%2.4×n/an/a
Nuvation Bio NUVBUnited States$1.34B-16%+654%-61%5.7×n/an/a
Generate Biomedicines GENBUnited States$1.34B-20%+56%-737%31.7×n/an/a
Taysha Gene Therapies TSHAUnited States$1.30B-27%-13%-2,998%170.1×n/an/a
Tyra Bioscience TYRAUnited States$1.35B-41%n/an/an/an/an/a
CanSino Biologics 6185.HKHong Kong$1.36B-23%+36%-4%6.8×n/an/a
Intellia Therapeutics NTLAUnited States$1.37B-20%-8%-821%21.3×n/an/a
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%408.9×n/an/a
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%50.1×n/an/a
Hualan Biological Vaccine 301207.SZChina$1.25B-29%-28%-7%9.0×33.2%-13.1%
AnaptysBio ANABUnited States$1.40B-22%+13%62%7.9×0.5%+25.6%
Pacific Shuanglin Bio-pharmacy 000403.SZChina$1.24B-21%+1%10%3.5×n/an/a
Absci ABSIUnited States$1.41B+65%-47%-9,155%835.7×n/an/a
uniQure QUREUnited States$1.42B-17%+28%-1,027%65.4×n/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%4.9×39.4%-2.5%
Liaoning Chengda Biotechnology 688739.SSChina$1.22B-14%-9%0%2.2×6.6%-7.0%
Mineralys Therapeutics MLYSUnited States$1.22B-52%n/an/an/an/an/a
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%2.3×n/an/a
Akums Drugs and Pharmaceuticals AKUMS.NSIndia$1.21B+38%+18%10%2.0×15.3%+9.9%
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%205.0×n/an/a

Questions

Which companies are Zhuhai Trinomab Pharmaceutical's closest peers?
The cockpit's peer set: Novavax (NVAX), Nuvation Bio (NUVB), Generate Biomedicines (GENB), Taysha Gene Therapies (TSHA), Tyra Bioscience (TYRA), CanSino Biologics (6185.HK), Intellia Therapeutics (NTLA), Oncolys BioPharma (4588.T).
Is Zhuhai Trinomab Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 164.8× against a peer median of 8.4×, 5th most expensive of 19 in its peer set.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.